Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?
Pharmacogenomics, Ahead of Print.
AbstractPurposeThe aim of the study was to develop a patient-reported outcome measure for patients with sarcoma —the Sarcoma Assessment Measure (SAM).Methods and resultsThe systematic development of SAM included a three-stage, mixed-methods study using semi-structured interviews, focus groups and questionnaires, with all stages involving patients from across the United Kingdom. In-depth interviews were conducted with 121 patients (50% male; aged 13 –82; with soft tissue sarcoma (62%), bone tumours (28%) and gastrointestinal stromal tumours (10%)). Content analysis of the interview transcripts identified 1415 po...
Authors: Mustapar N, Zawawi MSF, Tuan Sharif SE Abstract BACKGROUND: Diagnosis of malignant peripheral nerve sheath tumor (MPNST) is rather challenging due to its divergent morphologic heterogeneity and lack of specific ancillary test. The emergence of H3K27 trimethylation (H3K27me3) as a new immunohistochemistry (IHC) marker for MPNST have recently available to assist pathologists in differentiating MPNST from other histologic mimics. We aim to study the expression pattern of H3K27me3 in MPNST and its histologic mimickers and their association with the clinicopathological data. METHODOLOGY: A total of 59 benig...
CONCLUSIONS: We demonstrate that AZD3229 warrants clinical investigation as a new treatment for GIST patients based on its ability to inhibit both ATP-binding and A-loop mutations of KIT at clinically relevant exposures. PMID: 32220888 [PubMed - as supplied by publisher]
Journal of Laparoendoscopic&Advanced Surgical Techniques, Ahead of Print.
Cell Death &Disease, Published online: 23 March 2020; doi:10.1038/s41419-020-2390-7MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib
Authors: Arshad J, Ahmed J, Subhawong T, Trent JC Abstract Introduction: Gastrointestinal stromal tumor (GIST) is the most common malignant mesenchymal tumor of the gastrointestinal system. Multiple advances in the management of GIST from the discovery of KIT/PDGRA and other genetic alterations have led to the development of multiple tyrosine kinase inhibitors. Response assessment in GIST is determined with iRECIST (Response Evaluation Criteria in Solid Tumors), PERCIST (PET response criteria in solid tumors) or Choi criteria. Molecular genotyping of the tissue samples is the recent standard for diagnosis, treatmen...
In conclusion, YA GISTs are not similar to typical adult GISTs and also differ from paediatric GISTs, as described in the literature. In this series, we found a relatively high percentage of small intestine GIST, emergency presentation, 25% non-KIT/PDGFRA mutations and a relatively good survival.
Publication date: March 2020Source: The American Journal of Surgery, Volume 219, Issue 3Author(s): D. Patel, W.Lutfi P. Sweigert, E. Eguia, G. Abood, L. Knab, P.C. Kuo, M.S. Baker
Conclusions: ET is effective and safe for curative removal of GISTs in the upper gastrointestinal tract, and it can be a treatment of choice for patients with no metastasis. PMID: 32178486 [PubMed - as supplied by publisher]